

Daniela Maria Cardinale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4329482/daniela-maria-cardinale-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

8,368
citations

36
h-index

91
g-index

102
ext. papers

10,385
ext. citations

9.7
avg, IF

5.59
L-index

#	Paper	IF	Citations
94	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 1	3.3	1
93	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 513-521	5.9	4
92	Role of Cardiac Biomarkers in Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	5
91	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , 2021 , 26, 881-890	5	10
90	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 611-621	3.9	7
89	Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. <i>JAMA Oncology</i> , 2021 , 7, 924-932	13.4	1
88	Subclinical cardiac damage in cancer patients before chemotherapy. <i>Heart Failure Reviews</i> , 2021 , 1	5	0
87	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021 , 23, 1	2.1	1
86	How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice. <i>Kardiologia Polska</i> , 2021 , 79, 114-122	0.9	4
85	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.. <i>European Heart Journal</i> , 2021 ,	9.5	21
84	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , 2020 , 7, 1452-1466	3.7	8
83	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
82	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020 , 22, 1915-1960	12.3	127
81	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery: A Systematic Review and Meta-Analysis. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e007437	6.4	10
80	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 51-57	5.9	5
79	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020 , 41, 1720-1729	9.5	57
78	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1966-1983	12.3	61

77	Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
76	Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1190	5.6	2
75	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 2290-2309	12.3	22
74	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 480-504	220.7	16
73	Cardiotoxicity of Anthracyclines. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 26	5.4	66
72	Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection. <i>JACC: CardioOncology</i> , 2019 , 1, 84-102	3.8	5
71	Acute kidney injury: a common prognostic condition for different pathogenetic triggers?. <i>Journal of Thoracic Disease</i> , 2019 , 11, E112-E114	2.6	1
70	Oncologic therapies associated with cardiac toxicities: how to minimize the risks. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 359-374	3.5	3
69	Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	2
68	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019 , 24, e1034-e1043	5.7	4
67	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. <i>European Journal of Cancer</i> , 2018 , 94, 126-137	7.5	98
66	Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide. <i>Lung Cancer</i> , 2018 , 123, 155-159	5.9	15
65	The breast cancer patient in the cardioncology unit. <i>Journal of Thoracic Disease</i> , 2018 , 10, S4306-S4322	2.6	6
64	Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 245-256	3.8	44
63	Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. <i>Current Oncology Reports</i> , 2017 , 19, 55	6.3	16
62	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 9-42	12.3	189
61	Cardiotoxicity: Left Ventricular Dysfunction 2017 , 123-141		
60	Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3157-65	2.2	102

59	Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction. <i>Circulation Research</i> , 2016 , 119, 1339-1346	15.7	11
58	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. <i>Circulation: Heart Failure</i> , 2016 , 9, e002661	7.6	156
57	Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". <i>Circulation</i> , 2016 , 133, e363	16.7	3
56	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. <i>Circulation: Heart Failure</i> , 2016 , 9, e002843	7.6	84
55	Diagnostic Tests in Cardio-oncology 2016 , 313-343		
54	Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. <i>Annals of Surgery</i> , 2016 , 264, 244-51	7.8	33
53	Heart Failure in Oncologic Patients 2016 , 511-533		
52	Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss. <i>Current Cardiology Reports</i> , 2016 , 18, 51	4.2	42
51	Chemotherapy-induced cardiotoxicity: importance of early detection. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1297-1299	2.5	10
50	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 309-25	220.7	287
49	Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. <i>Circulation</i> , 2015 , 131, 1981-8	16.7	776
48	Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancer. <i>Tumori</i> , 2015 , 101, 64-71	1.7	3
47	Detection and monitoring of cardiotoxicity by using biomarkers: Pros and cons: Remarks on the international colloquium on cardioncology.. <i>Progress in Pediatric Cardiology</i> , 2015 , 39, 77-84	0.4	8
46	Cancer Cardiotoxicity and Cardiac Biomarkers. <i>Biomarkers in Disease</i> , 2015 , 73-105		0
45	Cardiac complications of chemotherapy: role of biomarkers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 313	2.1	24
44	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014 , 27, 911-39	5.8	722
43	Doxorubicin and trastuzumab regimen induces biventricular failure in mice. <i>Journal of the American Society of Echocardiography</i> , 2014 , 27, 568-79	5.8	49
42	The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 170-80	15.1	200

41	TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014 , 74, 385-91	2	11
40	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014 , 15, 1063-93	4.1	526
39	Cancer Cardiotoxicity and Cardiac Biomarkers 2014 , 1-26		
38	Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). <i>Ecancermedicalscience</i> , 2014 , 8, 433	2.7	11
37	Cardiac toxicity of anticancer agents. <i>Current Cardiology Reports</i> , 2013 , 15, 362	4.2	51
36	Cardiac toxicity in cancer survivors. <i>Cancer</i> , 2013 , 119 Suppl 11, 2131-42	6.4	36
35	Strategies to prevent and treat cardiovascular risk in cancer patients. <i>Seminars in Oncology</i> , 2013 , 40, 186-98	5.5	72
34	Managing cardiotoxicity of chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013 , 15, 410-24	2.1	28
33	Reply to R. Steiner et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1380	2.2	
32	Using cardiac biomarkers and treating cardiotoxicity in cancer. <i>Future Cardiology</i> , 2013 , 9, 105-18	1.3	20
31	Postoperative B-type natriuretic peptide for prediction of major cardiac events in patients undergoing noncardiac surgery: systematic review and individual patient meta-analysis. <i>Anesthesiology</i> , 2013 , 119, 270-83	4.3	70
30	Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. <i>Journal of Cardiovascular Echography</i> , 2011 , 21, 32-41	0.6	
29	Treatment and prevention of cardiotoxicity due to anticancer therapy. <i>Journal of Cardiovascular Echography</i> , 2011 , 21, 92-100	0.6	1
28	Treating asymptomatic chemotherapy-induced cardiac dysfunction: a chance that cardiologists and oncologists should not miss. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1790; author reply 1790-1	15.1	2
27	Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. <i>Herz</i> , 2011 , 36, 325-32	2.6	13
26	Reply to S. Goel et al and P.A. Kavsak et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e178-e179	2.2	
25	Role of biomarkers in cardioncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 1937-48	5.9	32
24	Managing cardiac risk factors in oncology clinical trials. <i>Texas Heart Institute Journal</i> , 2011 , 38, 266-7	0.8	4

23	Cardiac dysfunction after cancer treatment. <i>Texas Heart Institute Journal</i> , 2011 , 38, 248-52	0.8	11
22	Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3910-6	2.2	463
21	Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 213-20	15.1	732
20	Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk. <i>Biomarkers</i> , 2010 , 15, 259-65	2.6	11
19	Role of biomarkers in chemotherapy-induced cardiotoxicity. <i>Progress in Cardiovascular Diseases</i> , 2010 , 53, 121-9	8.5	113
18	The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. <i>Progress in Cardiovascular Diseases</i> , 2010 , 53, 88-93	8.5	65
17	Circulating cytochrome c as potential biomarker of impaired reperfusion in ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2010 , 106, 1443-9	3	12
16	Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 688-95	1.9	137
15	Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008 , 10, 486-95	2.1	27
14	Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer. <i>Circulation</i> , 2007 , 115, 1339-44	16.7	78
13	Troponin I and cardiovascular risk stratification in patients with testicular cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3508; author reply 3508-9	2.2	12
12	Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. <i>Circulation</i> , 2006 , 114, 2474-81	16.7	696
11	Acute coronary syndrome induced by oral capecitabine. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 251-3	3.8	27
10	Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. <i>International Journal of Cardiology</i> , 2006 , 111, 120-6	3.2	67
9	N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. <i>Clinical Chemistry</i> , 2005 , 51, 1405-10	5.5	172
8	Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. <i>Circulation</i> , 2004 , 109, 2749-54	16.7	652
7	Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. <i>Chest</i> , 2004 , 126, 1412-6	5.3	51
6	Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. <i>Clinical Chemistry</i> , 2003 , 49, 248-52	5.5	94

5	Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. <i>Annals of Oncology</i> , 2002 , 13, 710-5	10.3	222
4	Intrapericardial treatment of neoplastic pericardial effusions. <i>Herz</i> , 2000 , 25, 787-93	2.6	28
3	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 517-22	15.1	385
2	Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. <i>Annals of Thoracic Surgery</i> , 1999 , 68, 1827-31	2.7	69
1	Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. <i>American Journal of Cardiology</i> , 1991 , 68, 492-7	3	26